Trestolone acetate
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | Orgasteron acetate; MENT acetate; CDB-903; NSC-69948; U-15614; 7α-Methyl-19-nortestosterone 17β-acetate; 7α-Methylestr-4-en-17β-ol-3-one 17β-acetate |
| Routes of administration |
Intramuscular injection |
| Drug class | Androgen; Anabolic steroid; Androgen ester; Progestogen; Antigonadotropin |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30O3 |
| Molar mass | 330.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trestolone acetate (USAN; developmental code names CDB-903, NSC-69948, U-15614; also known as 7α-methyl-19-nortestosterone 17β-acetate (MENT acetate) and 7α-methylestr-4-en-17β-ol-3-one 17β-acetate) is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed. It is an androgen ester – specifically, the C17 acetate ester of trestolone (7α-methyl-19-nortestosterone; MENT). The medication was first described in 1963.
See also
| ER |
|
||||||
|---|---|---|---|---|---|---|---|
| GPER |
|
||||||
| PR |
|
||||||
|---|---|---|---|---|---|---|---|
|
mPR (PAQR) |
|
||||||